Cencora, Inc. announces the acceleration of acquiring OneOncology to enhance their management services organization and align with growth-oriented investments.
OneOncology, a physician-led national platform focused on oncology, will contribute to Cencora's enterprise growth according to the announcement.
The transaction values OneOncology at $7.4 billion, with Cencora acquiring the majority of outstanding equity interests for approximately $5.0 billion.
Strategic Acquisition
Cencora's acquisition of OneOncology strengthens its solutions in specialty, leading with market leaders and enhancing patient access to pharmaceuticals.
Financial Details
The transaction values OneOncology at $7.4 billion, with Cencora acquiring the majority of equity interests for approximately $5.0 billion.
Expected Impact
The acquisition is expected to be neutral to Cencora's adjusted diluted EPS in the first twelve months post-close, showcasing a positive outlook on growth.
- The acquisition of OneOncology is aligned with Cencora's pharmaceutical-centric strategy to support specialty physicians, market leaders, and patient access to innovative treatments.
- Cencora's expected long-term guidance reflects the strategic importance of OneOncology in driving value for stakeholders and enhancing patient outcomes.
Cencora's acquisition of OneOncology marks a significant step towards strengthening its position in the healthcare landscape, with a focus on specialty solutions and patient-centric care. The strategic move reflects Cencora's commitment to driving growth and innovation in community oncology.